Benralizumab reduces asthma exacerbations in severe eosinophilic asthma patients over 24 weeks.
New Asthma Shot May Cut Severe Attacks to Zero
This prospective, single-arm, multicenter, phase IV study evaluated benralizumab in 138 benralizumab-naïve adults (18–75 years) with severe …
A new injection appears safe and effective at reducing severe asthma attacks in adults.
Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD.
A Tricky Immune Messenger Behind Severe Asthma
This systematic review evaluated IL-5-targeted therapies, multi-target combination therapies, bispecific antibodies, and small-molecule inhi…
A protein called IL-5 fuels severe asthma, but new drugs targeting multiple immune pathways at once may finally help patients who haven't re…